Article

Teva UK launches generic latanoprost

Teva UK Ltd. has launched a generic version of latanoprost 0.005% eye drops solution (Xalatan, Pfizer). Latanoprost is indicated for the treatment of elevated IOP in patients who have open-angle glaucoma or ocular hypertension.

Castleford, England-Teva UK Ltd. has launched a generic version of latanoprost 0.005% eye drops solution (Xalatan, Pfizer).

Latanoprost is indicated for the treatment of elevated IOP in patients who have open-angle glaucoma or ocular hypertension.

“As the leading generics company in the country and with the widest portfolio of our competitors, Teva continues to lead with strong product launches and patent expired products,” said Kim Innes, Teva’s commercial director. “This is our inaugural product launch for 2012 and our first day-one patent expiry of the year.”

For more articles in this issue of Ophthalmology Times eReport, click here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) CCOI sets the stage for global ophthalmic innovation at Stanford Summit on July 23
(Image credit: Ophthalmology Times) Accelerating eye health innovation through CCOI – Stanford Summit
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
© 2025 MJH Life Sciences

All rights reserved.